BofA Securities initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA), ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease. • VERA is facing resistance from sellers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback